Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0527 • ACR Convergence 2020
Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicenter Israeli Experience
Nancy Agmon-Levin¹, Mark Berman², Liora Harel³, Merav Lidar⁴, Soad Hajyahia¹ and Daphna Paran⁵, ¹Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Scheider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel, Petach Tikva, Israel, ⁴Rheumatology unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Hod Hasharon, Israel, ⁵Department of Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: The clinical manifestations of the antiphospholipid syndrome (APS) are heterogeneous and related to anti-phospholipid antibodies (aPL). There is some evidence that B cells are…
Abstract Number: 0835 • ACR Convergence 2020
Pathogenic Effect of Chronic Stress-induced interleukin-12/23p40 on Neuropsychiatric System in Lupus-prone Mouse
Nobuya Abe¹, Kenji Oku¹, Yuichiro Fujieda¹, Nobuhiko Takahashi², Kohei Karino¹, Michihito Kono¹, Masaru Kato¹, Yuki Tanaka³, Rie Hasebe⁴, Olga Amengual¹, Miwako Yamasaki⁵, Masahiko Watanabe⁵, Masaaki Murakami³ and Tatsuya Atsumi⁶, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ²Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ³Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁴Biomedical Animal Research Laboratory, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁵Department of Anatomy, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan
Background/Purpose:Neuropsychiatric system is one of the major organs affected in systemic lupus erythematosus (SLE). However, the pathogenesis of neuropsychiatric SLE (NPSLE) has not been fully…
Abstract Number: 0855 • ACR Convergence 2020
Treatment of SLE with or Without Nephritis with the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study
Richard Furie¹, Samir Parikh², Kenneth Harvey³, Christopher Kirk⁴, Darrin Bomba⁴ and MK Farmer⁵, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²The Ohio State University, Columbus, OH, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc, San Francisco, CA, ⁵Kezar, Raleigh, NC
Background/Purpose: Immunoproteasome inhibition has demonstrated meaningful therapeutic potential in preclinical models of systemic lupus erythematosus (SLE) and lupus nephritis (LN). KZR-616 is a first-in-class selective…
Abstract Number: 0887 • ACR Convergence 2020
Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network
Simon Helfgott¹, Jeremy Broestl², Kent Kwas Huston³, Deepali Rane², Jasvinder Singh⁴, Nehad Soloman⁵ and Colin Edgerton⁶, ¹BWH- HMS, Boston, MA, ²Trio Health, Louisville, CO, ³Kansas City Physician Partners, Kansas City, MO, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁶Articularis Healthcare, Summerville, SC
Background/Purpose: Systemic lupus erythematosus (SLE) treatments include steroids, antimalarials, immunosuppressants and/or biologics, though the use of biologics has been reported as minimal in claim-based studies…
Abstract Number: 0990 • ACR Convergence 2020
Interferon Lambda Promotes Human Plasma Cell Differentiation in Lupus and Healthy Donors
Jennifer Barnas¹, Jennifer Albrecht¹ and Jennifer Anolik¹, ¹University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by antinuclear autoantibodies produced by plasma cells. Type I interferon (IFN) are cytokines which…
Abstract Number: 1143 • ACR Convergence 2020
The Influence of YouTube on Spreading Awareness and Patient Education Regarding Systemic Lupus Erythematosus
Priyatha Garlapati¹, Jasmeen Uppal¹, Sarwat Umer² and Samina Hayat², ¹LSU Shreveport, Shreveport, ²LSU Shreveport, Shreveport, LA
Background/Purpose: A large global survey released by the World Lupus Federation showed that the awareness of SLE is low and many individuals have never heard…
Abstract Number: 1270 • ACR Convergence 2020
Trend of Survival of a Cohort of Patients with Systemic Lupus Erythematosus over 25 Years
Chi Chiu Mok¹, Ling Yin Ho¹, Kar Li Chan², Sau Mei Tse² and Chi Hung To³, ¹Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: Background: Few studies of systemic lupus erythematosus (SLE) have a follow-up duration long enough to evaluate the time trend of survival, particularly in Asian…
Abstract Number: 1286 • ACR Convergence 2020
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus by Physician Global Assessment of Disease Activity
May Choi¹, Emma Stevens², Hongshu Guan², Daniel Li³, Jack Ellrodt⁴, Benjamin Kargere⁴, Tianrun Cai², Kazuki Yoshida⁵, Brendan Everett² and Karen Costenbader⁶, ¹Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital, Boston, MA, ³Harvard, Columbus, OH, ⁴Williams College, Williamstown, ⁵Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The risk of cardiovascular disease (CVD), including myocardial infarction and stroke, is higher in SLE than in the general population. The excess risk of…
Abstract Number: 1302 • ACR Convergence 2020
Exploration of Machine Learning Methods in Predicting Systemic Lupus Erythematosus Hospitalizations
April Jorge¹, Zhiyao Wu², Tashrif Chowdhury² and Yijun Zhao², ¹Massachusetts General Hospital, Boston, MA, ²Fordham University, Computer and Information Sciences Department, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease associated with increased morbidity and mortality, and severe SLE flares can lead to hospitalizations. Our objective…
Abstract Number: 1512 • ACR Convergence 2020
Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis
Andrea Fava¹, Avi Rosenberg², Serena Bagnasco², Paride Fenaroli², Jessica Li¹, Jose Monroy-Trujillo², Derek Fine² and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: . Pure membranous (class V) lupus nephritis is considered a less aggressive phenotype, but renal fibrosis and chronic kidney disease may develop. Whether this…
Abstract Number: 1671 • ACR Convergence 2020
Identifying Rare Genetic Variants in Childhood-onset Monogenic Systemic Lupus Erythematosus
Melissa Misztal¹, Fangming Liao², Sergey Naumenko³, Andrea Knight⁴, Daniela Dominguez⁵, JingJing Cao², Declan Webber⁶, Bhooma Thiruvahindrapuram⁷, Deborah Levy⁶, Andrew Paterson², Earl D. Silverman⁸ and Linda Hiraki⁹, ¹Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Oakville, ON, Canada, ²Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Canada, ³The Centre for Computational Medicine, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ⁸Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada
Background/Purpose: Among children diagnosed with systemic lupus erythematosus (SLE), there exists monogenic forms of SLE, where rare variants in a single gene lead to disease.…
Abstract Number: 1773 • ACR Convergence 2020
Worse Maternal and Fetal Outcomes Among Hospitalized U.S. Pregnant Women with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)
Christine Anastasiou¹, Laura Trupin¹, Patricia Katz², Zara Izadi³, Milena Gianfrancesco¹, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, Novato, CA, ³University of California San Francisco, San Francisco, CA, ⁴University of California, San Francisco, Atherton, CA, ⁵UCSF, San Francisco, CA
Background/Purpose: Prior studies suggest women with SLE and RA may have higher age-adjusted risk of adverse pregnancy outcomes. We evaluated maternal and fetal complications and…
Abstract Number: 1800 • ACR Convergence 2020
Association of Air Pollution with Systemic Lupus Erythematosus Disease Activity in the Central Valley of California
Mosaab Mohameden¹, Ali H.Ali², Zi Ying Li², Yabsira Abejie³, Ratnali Jain² and Candice Reyes Yuvienco⁴, ¹University of Cincinnati College of Medicine, Cincinnati, OH, ²University of California San Francisco Fresno, Fresno, CA, ³Floyd B. Buchanan High School, Fresno, CA, ⁴University of California San Francisco Fresno, Clovis, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex multisystem autoimmune disease that affects at least 300,000 people in the United States creating a substantial socioeconomic…
Abstract Number: 1818 • ACR Convergence 2020
IgG and IgA Autoantibodies Against L1 ORF1p Expressed in Granulocytes Correlate with Granulocyte Consumption and Disease Activity in Pediatric Systemic Lupus Erythematosus
Kennedy Ukadike¹, Kathryn Ni¹, Victoria Carter¹, Martin Taylor², John LaCava³, Lauren Pachman⁴, Xiaoxing Wang¹, Mary Eckert⁵, Anne Stevens¹, Christian Lood¹ and Tomas Mustelin¹, ¹University of Washington, Seattle, WA, ²Massachusetts General Hospital, Boston, MA, ³Rockefeller University, New York, NY, ⁴Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL, ⁵Seattle Children's Hospital, Seattle, WA
Background/Purpose: To quantitate autoantibodies against the RNA-binding p40 (ORF1p) protein encoded by the L1 retroelement, expression of p40 itself, and markers of neutrophil death in…
Abstract Number: 1834 • ACR Convergence 2020
Biomarker Analysis of IFN-I Modulation in JNJ-839: First-in-Human Study for Systemic Lupus Erythematosus
Ashley Orillion¹, Loqmane Seridi¹, Matteo Cesaroni², Jessica Schreiter¹, Jacqueline Benson³, William Stohl⁴, Walter Winn Chatham⁵, Richard Alan Furie⁶, Thi-Sau Migone⁷, Stanley Marciniak¹, Zhenling Yao¹, Bhaskar Srivastava¹, Marc Chevrier² and Jarrat Jordan¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Spring House, ³Janssen Research & Development, LLC, South San Francisco, CA, ⁴University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁷Independent Consultant, Spring House
Background/Purpose: JNJ-839 is a fully human neutralizing antibody selective to human IFN-ω and IFN-α subtypes. Here we report the exploratory biomarker analyses of a Phase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].